Work

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

Year: 2020

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet Neurology

DOI: 10.1016/s1474-4422(20)30066-1

Authors: Masayuki Tahara, Tomoko Oeda, Kazumasa Okada, Takao Kiriyama, Kazuhide Ochi, Hirofumi Maruyama, Hikoaki Fukaura, Kyoichi Nomura, Yuko Shimizu, Masahiro Mori, Ichiro Nakashima, Tatsuro Misu, Atsushi Umemura, Kenji Yamamoto, Hideyuki Sawada

Institutions: National Hospital Organization, Utano Hospital, University of Occupational and Environmental Health Japan, Nara Medical University, Hiroshima University, Saitama Medical University, Tokyo Women's Medical University, Chiba University, Tohoku Medical and Pharmaceutical University, Tohoku University

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Japan Agency for Medical Research and Development, Ministry of Health, Labour and Welfare, Kyoto University, Fukushima University, Japan Society for the Promotion of Science

Awards: The analysis of aberrant machinery mediated by intraneural and extraneural alpha-synuclein oilgomers, G3848803491, Cellular immunnogenesis in MOG antibody related encephalomyelitis, 視神経脊髄炎の再発に対するリツキシマブの有用性を検証する第II/III相多施設共同プラセボ対照無作為化試験

OpenAlex ID: W3012054652

FWCI: 26.55

Cites: 31

Cited by: 388

Related to: 10